VERTEX PHARMACEUTICALS INC (VRTX)       323.1  +3.12 (+0.98%)

323.1  +3.12 (+0.98%)

US92532F1003 - Common Stock - After market: 323.1 0 (0%)

VERTEX PHARMACEUTICALS INC323.1

NASDAQ:VRTX (1/31/2023, 7:07:35 PM)+3.12 (+0.98%)

After market: 323.1 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 01-24 2023-01-24/amc Earnings (Next) 05-03 2023-05-03/amc
Ins Owners 0.18% Inst Owners 92.98%
Market Cap 82.94B Shares 256.69M
PE 22.28 Fwd PE 20.01
Dividend Yield N/A Analysts 77.14
IPO 07-24 1991-07-24

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VRTX Daily chart

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 3,900 full-time employees. The firm is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The firm's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The firm has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.

Company Info

VERTEX PHARMACEUTICALS INC

50 Northern Avenue

Boston MASSACHUSETTS 02210

P: 16173416393.0

CEO: Reshma Kewalramani

Employees: 3900

Website: https://www.vrtx.com/

VRTX News

News Image3 hours ago - The Motley FoolA New Bull Market Could Arrive in February: 3 Stocks to Buy Now

The bulls could be about to take over again. And these stocks are poised to be big winners.

News Imagea day ago - The Motley Fool3 Things About CRISPR Therapeutics That Smart Investors Know

The gene-therapy specialist's near-term outlook is quite bullish.

News Image5 days ago - The Motley FoolThe Best Stocks to Invest $20,000 in Right Now

These healthcare giants have plenty of room left to run.

News Image5 days ago - The Motley Fool3 Healthcare Stocks to Buy and Hold for the Next 10 Years

These companies have the therapies to boost revenue for a decade.

News Image7 days ago - InvestorPlace3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

News Image7 days ago - InvestorPlace7 Cream-of-the-Crop Stocks to Buy Today

Fast-growing, underappreciated stocks to buy are trading at a steep discount and will reward investors as they rise in value.

VRTX Twits

Here you can normally see the latest stock twits on VRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example